H.C. Wainwright Thinks Karyopharm Therapeutics’ Stock is Going to Recover


In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Karyopharm Therapeutics (KPTI), with a price target of $30. The company’s shares opened today at $9.06, close to its 52-week low of $8.01.

According to TipRanks.com, White is a 5-star analyst with an average return of 13.7% and a 45.8% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.

Karyopharm Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $22.67.

See today’s analyst top recommended stocks >>

Based on Karyopharm Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $48.08 million. In comparison, last year the company had a GAAP net loss of $39.04 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, The engages in the discovery, development, and commercialization of drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts